Compare Moderna, Inc. (MRNA) vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares — how do they compare? Moderna, Inc. trades at $221.25 (market cap $90.35B), while National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.72 (market cap $78.99B). The key difference: Moderna, Inc. and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares are close in size by market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NGG | |
|---|---|---|
Market Cap | $90.35B | $78.99B |
Volume | 16,579,584 | 740,402 |
Sector | Health | Utilities |
52-Week High | $226.30 | $93.93 |
52-Week Low | $22.36 | $73.54 |
Typical Hold Time | 59 Days | — |
Enterprise Value | $86.50B | $137.22B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.
The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →
